Most Read Articles
28 Nov 2019
The occurrence and severity of hidradenitis suppurativa (HS) are associated with micronutrient status and obesity, suggesting that weight loss and dietary modifications should be considered in the treatment of HS patients, according to the results of a systematic review and meta-analysis.
10 Dec 2019
Oral H1-antihistamines are the initial treatment of choice for allergic rhinitis (AR) and chronic urticaria in the primary care setting. However, in a diverse population of patients with AR and urticaria, primary care physicians are faced with the challenge of prescribing the best therapy amid a wide armamentarium of antihistamines available.
27 Nov 2019
Earlier-onset atopic dermatitis in children appears to correlate with stronger persistence over time and worse disease control, a recent study has found.

Rupatadine safe, effective for treating chronic spontaneous urticaria

20 Aug 2018

Rupatadine effectively relieves pruritus in patients with chronic spontaneous urticaria (CSU) and is well tolerated without serious or clinically significant adverse effects, according to the results of a phase III trial.

The trial randomized adolescent (n=15) and adult (n=261) Japanese patients to treatment with rupatadine at either 10 mg (n=91) or 20 mg (n=91) or placebo (n=94) once daily for 2 weeks. Total pruritus score (TPS; sum of daytime and night-time scores) was assessed as the primary endpoint.  

Efficacy results favoured both rupatadine doses. At the end of treatment, changes in mean TPS were greater with the 10- and 20-mg doses vs placebo (differences, −1.956 and −2.121, respectively; analysis of covariance, p<0.001 for both).

Adverse events (AEs) occurred in 20.9 percent of patients in the 10-mg group, 17.4 percent in the 20-mg group and in 8.5 percent in the placebo group. Somnolence was the only adverse reaction associated with the study drug, documented in 10 patients who received the lower dose and in nine of those who received the higher dose. There were no reports of serious or clinically significant AEs.

The present data show that rupatadine is effective at a dose of 10 mg once daily in the treatment of CSU and can be safely increased to 20 mg once daily, as necessary, researchers said. Furthermore, the results provide positive evidence for the effect of the drug in adolescent patients, despite the small sample size.

Study limitations include the short duration of rupatadine treatment and the fact that dose titration was not an option owing to the administration of fixed doses.

Additional studies are required to characterize the clinical benefits and risk of long-term rupatadine use and dose increase from 10–20 mg, researchers added.

Editor's Recommendations
Most Read Articles
28 Nov 2019
The occurrence and severity of hidradenitis suppurativa (HS) are associated with micronutrient status and obesity, suggesting that weight loss and dietary modifications should be considered in the treatment of HS patients, according to the results of a systematic review and meta-analysis.
10 Dec 2019
Oral H1-antihistamines are the initial treatment of choice for allergic rhinitis (AR) and chronic urticaria in the primary care setting. However, in a diverse population of patients with AR and urticaria, primary care physicians are faced with the challenge of prescribing the best therapy amid a wide armamentarium of antihistamines available.
27 Nov 2019
Earlier-onset atopic dermatitis in children appears to correlate with stronger persistence over time and worse disease control, a recent study has found.